Literature DB >> 26397020

Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions.

Victor L Villemagne1, Nobuyuki Okamura2.   

Abstract

In vivo tau imaging allows a deeper understanding of tau deposition in the brain, providing insights into the causes, diagnosis and treatment of primary and secondary tauopathies such as Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar degeneration. The cross-sectional and longitudinal assessment of the temporal and spatial patterns of tau deposition in the brain will allow a better understanding of the role tau plays in ageing as well as its relationship with cognition, genotype, and neurodegeneration. It is likely that selective tau imaging could be used as a diagnostic and prognostic biomarker of disease progression, as well as a surrogate marker for monitoring of efficacy and patient recruitment for disease-specific therapeutic trials.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26397020     DOI: 10.1016/j.conb.2015.09.002

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  24 in total

1.  Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease.

Authors:  W Robert Bell; Yang An; Yusuke Kageyama; Collin English; Gay L Rudow; Olga Pletnikova; Madhav Thambisetty; Richard O'Brien; Abhay R Moghekar; Marilyn S Albert; Peter V Rabins; Susan M Resnick; Juan C Troncoso
Journal:  Alzheimers Dement       Date:  2018-12-11       Impact factor: 21.566

Review 2.  Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Authors:  Scott E Counts; Milos D Ikonomovic; Natosha Mercado; Irving E Vega; Elliott J Mufson
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

3.  AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure.

Authors:  Shruti Mishra; Brian A Gordon; Yi Su; Jon Christensen; Karl Friedrichsen; Kelley Jackson; Russ Hornbeck; David A Balota; Nigel J Cairns; John C Morris; Beau M Ances; Tammie L S Benzinger
Journal:  Neuroimage       Date:  2017-07-26       Impact factor: 6.556

4.  Tau PET and tauopathies.

Authors:  Karl Herholz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08       Impact factor: 9.236

Review 5.  Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials.

Authors:  Jared R Brosch; Martin R Farlow; Shannon L Risacher; Liana G Apostolova
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

6.  The association between tau PET and retrospective cortical thinning in clinically normal elderly.

Authors:  Molly R LaPoint; Jasmeer P Chhatwal; Jorge Sepulcre; Keith A Johnson; Reisa A Sperling; Aaron P Schultz
Journal:  Neuroimage       Date:  2017-05-22       Impact factor: 6.556

7.  Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects.

Authors:  Dean F Wong; Robert A Comley; Hiroto Kuwabara; Paul B Rosenberg; Susan M Resnick; Susanne Ostrowitzki; Cristina Vozzi; Frank Boess; Esther Oh; Constantine G Lyketsos; Michael Honer; Luca Gobbi; Gregory Klein; Noble George; Lorena Gapasin; Kelly Kitzmiller; Josh Roberts; Jeff Sevigny; Ayon Nandi; James Brasic; Chakradhar Mishra; Madhav Thambisetty; Abhay Mogekar; Anil Mathur; Marilyn Albert; Robert F Dannals; Edilio Borroni
Journal:  J Nucl Med       Date:  2018-05-04       Impact factor: 10.057

Review 8.  Molecular and cellular pathophysiology of preclinical Alzheimer's disease.

Authors:  Elliott J Mufson; Milos D Ikonomovic; Scott E Counts; Sylvia E Perez; Michael Malek-Ahmadi; Stephen W Scheff; Stephen D Ginsberg
Journal:  Behav Brain Res       Date:  2016-05-13       Impact factor: 3.332

9.  A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date.

Authors:  Bern G Lee; MacKenzie J Leavitt; Charles B Bernick; Gabriel C Leger; Gil Rabinovici; Sarah J Banks
Journal:  J Neurotrauma       Date:  2018-06-12       Impact factor: 5.269

10.  Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.

Authors:  Rachel F Buckley; Bernard Hanseeuw; Aaron P Schultz; Patrizia Vannini; Sarah L Aghjayan; Michael J Properzi; Jonathan D Jackson; Elizabeth C Mormino; Dorene M Rentz; Reisa A Sperling; Keith A Johnson; Rebecca E Amariglio
Journal:  JAMA Neurol       Date:  2017-12-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.